Bank of America sees increasing risks for employers with weight-loss drug coverage
The eye-popping projections for weight-loss drug sales depend on insurers agreeing to provide coverage for the expensive treatments, and momentum appears to be building on that front. But Bank of America analyst Allen Lutz is wondering whether employers know how much risk they’re taking. The hope is that spending today on GLP-1 drugs like Ozempic, … Read more
